Could a revolutionary treatment combination redefine gout management while safeguarding kidney health? New findings reveal that a low daily dosage of mycophenolate mofetil (MMF), when paired with pegloticase, may significantly enhance treatment outcomes for patients grappling with both chronic kidney disease (CKD) and uncontrolled gout.
This intriguing research, set to be presented by Dr. Luana Pillon and her team at the upcoming 2025 American Society of Nephrology Kidney Week, indicates that this treatment strategy is not only well-tolerated but also effectively reduces serum uric acid (sUA) levels while stabilizing kidney function.
While the combination of pegloticase and MMF shows promise, researchers caution that there are potential risks, such as gastrointestinal issues and the possibility of infections. Historically, studies have demonstrated that combining 8 mg of pegloticase administered biweekly with 1,000 mg of MMF taken twice daily resulted in a higher percentage of patients achieving their target sUA levels, alongside fewer infusion-related reactions, compared with a placebo group.
In this particular small, retrospective study, the research team investigated a reduced MMF dosage of 500 mg or less taken twice a day. Utilizing anonymized patient data from community nephrology clinics, they focused on a cohort of fifteen CKD patients.
Among these patients, fourteen were prescribed MMF at a dosage of 500 mg twice daily, while one individual received it once daily. Out of the entire cohort, six patients were classified as having stage 2-3a CKD, and nine were categorized in the more severe stage of 3b-5 CKD. Notably, tophi—crystal deposits in tissues indicative of chronic gout—were identified in around two-thirds (66%) of patients with milder CKD, and in a striking 89% of those with more advanced kidney disease.
Patients with stage 2-3a CKD averaged 19 pegloticase infusions over a period of 188 days, while those in the 3b-5 CKD stage averaged twelve infusions over a longer duration of 287 days. Remarkably, utilizing this lower MMF dose alongside pegloticase resulted in a swift reduction of sUA levels to below 0.2 mg/dL, and these low levels were effectively sustained throughout the treatment period. However, it is worth mentioning that one patient with stage 2 CKD had to stop the pegloticase treatment due to side effects.
Encouragingly, kidney function remained stable for the majority of patients, including those in advanced stages of CKD. An estimated glomerular filtration rate (eGFR), which is crucial for assessing kidney health, showed stability or even improvement in 50% of the stage 2-3a CKD patients and 78% of those with stage 3b-5 CKD.
Moreover, the study noted a reduction in gout symptoms and a lower occurrence of adverse events among both the less serious and more advanced cohorts of CKD patients.
This research was made possible with support from Amgen, and it raises important questions about the future of gout treatment. But here's where it gets controversial... Can the benefits of this combination therapy outweigh the potential risks, or could the adverse effects overshadow the positives? We invite you to share your thoughts and engage in discussion—do you agree with the findings, or do you believe there are more significant concerns that should be addressed in treatment strategies for gout patients with CKD?
